Course of COVID-19 in children under one year of age depending on the type of antipyretic therapy at the pre-hospital stage

Vasilkova et al., Pharmacology & Pharmacotherapy, doi:10.46393/27132129_2026_2_86-92, Jun 2026
Early treatmentRetrospective · 56 patients · Russia
Acetaminophen for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
00.511.52+
← Acetaminophen
reduces risk
Acetaminophen
increases risk →
Higher ICU admission and progression
Not statistically significant · p = 0.53 (ICU admission) and p = 0.22 (progression) Study compares with ibuprofen, results vs. placebo may differ

Acetaminophen for COVID-19

2nd treatment shown to increase risk in November 2020, now with p = 0.00000021 from 28 studies, but still recommended in 103 countries.
Retrospective 86 infants under 1 year old comparing pre-hospital antipyretic therapy with Viburcol, paracetamol, and ibuprofen. No statistically significant differences were found between groups for hospitalization duration, disease severity, ICU transfer rate, oxygen saturation, or CT changes. There was a non-significant trend toward higher severity and ICU transfers in the paracetamol group. Viburcol is marketed differently and may have significant confounding by indication, with paracetamol and ibuprofen more likely used for more serious cases. Therefore the comparison between paracetamol and ibuprofen may be most informative, however potential confounding remains - ibuprofen is not licensed for the youngest group that may have higher risk (favors ibuprofen), and ibuprofen may be used as a second line treatment when paracetamol fails (favors paracetamol).
Paracetamol is also known as acetaminophen, Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan.
Study covers acetaminophen and ibuprofen.
OutcomeImprovementEffect · pTreatmentControl
risk of ICU admission 60.0% higher · RR 1.60 · p = 0.53 60.0% higherRR 1.60p = 0.53 8 of 28 (28.6%) 5 of 28 (17.9%) treatment 8 of 28 (28.6%), control 5 of 28 (17.9%)
mean case severity score 18.8% higher · relative time 1.19 · p = 0.22 18.8% higherrelative time 1.19p = 0.22 mean 1.71 (±0.81) n=28 mean 1.44 (±0.81) n=28 mean 1.71 (±0.81) n=28, mean 1.44 (±0.81) n=28

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Vasilkova et al., 2 Jun 2026, retrospective, Russia, peer-reviewed, 2 authors, this trial compares with another treatment - results may be better when compared to placebo.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Russia Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Russia favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Russia Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Zimbabwe Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Russia favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: ПЕДИА&РИЯ/PEDIATRICS 9:Ч:НИ: COVID-19 У 2:9:Й 2О AО2А B CАBИDИEОD9И О9 BИ2А FА6ОGОНИFАHI:Й 9:6АGИИ НА 2ОAОDGИ9АЛKНОE L9АG: Д.". Ва%&л()ова, ,.-. .&/ал(0&)ов 12345 В4 «-60о-57ал(%)&8 9о%:да7%<ве00ы8 мед&@&0%)&8 :0&ве7%&<е<» A&0Bд7ава Cо%%&&, 9. DелEF&0%) Адрес для переписки: !а#и%&к()а *и+и, -и,./к()+а, diva2905@mail.ru Кл,-е.ые сл0.1: COVID-19, 0/1и 2/3)(4( 4(0а 5и6+и, 7%а0/+89, 5а3(2(+и5а:;а, 1/3а2и,, !и.<3к(%, 2а3а8/1а7(%, и.<23(=/+, SARS-CoV-2, 0(4(#2и1а%&+9> ?1а2, %и@(3а0ка, D-0и7/3, 1,5/#1& 6а.(%/)а+и,, 4(7/(2а1и,, .и(3/4<%,8и(++а, 1/3а2и, 2ля цитир0.1ния: !а#и%&к()а *.-., Aи;а%&+ик() B.C. D/E/+и/ COVID-19 <F0/1/> 0(F4(0а )F6а)и#и7(#1и (1F)и0а 5а3(2(+и5а:;/> 1/3а2ии +аF0(4(#2и1а%&+(7 ?1а2/. Gа37ак(%(4и, & Gа37ак(1/3а2и,. 2026; 2: 86–92. DOI 10.46393/27132129_2026_2_86–92 6ез,ме A3()/0/+( и##%/0()а+и/, 2(#),;/++(/ и6<E/+и: к%и+иE/#ки@ 23(,)%/+и> и+=/к8ии SARS-CoV-2 <F 0/1/> 2/3)(4( 4(0а 5и6+и )F2/3и(0 2021–2023 44. H#1а+()%/+(, E1(F1/E/+и/ 6а.(%/)а+и, 23/и7<;/#1)/++( .9%( %/4ки7, ./6F%/1а%&+9@ и#@(0(). D,5/%9/ #%<Eаи а##(8ии3()а%и#& #F+а%иEи/7 к(7(3.и0+(> 2а1(%(4ии иF#(23()(50а%и#& @а3ак1/3+97и и67/+/+и,7и %а.(3а1(3+9@ 7а3к/3() )(#2а%/+и,, аF1ак5/ <3()+, D-0и7/3а. A3и #3а)+и1/%&+(7 а+а%и6/ 13/@ 43<22 2а8и/+1(), )90/%/++9@ )F6а)и#и7(#1и (1F)и0а 5а3(2(+и5а:;/> 1/3а2ии +аF0(4(#2и1а%&+(7 ?1а2/ (!и.<3к(%®, 2а3а8/1а7(%, и.<23(=/+), #1а1и#1иE/#ки 6+аEи79@ 3а6%иEи> 2(F .(%&Iи+#1)< к%и+иE/#ки@ иF %а.(3а1(3+9@ 2(ка6а1/%/> +/F)9,)%/+(, 6аFи#к%:E/+и/7 2()9I/++(4( <3()+, D-0и7/3а )F43<22/ и.<23(=/+а. D/+0/+8ии кF.(%// 1,5/%(7< 1/E/+и: иF.(%// )9#(к(> Eа#1(1/ 2/3/)(0а )F(10/%/+и/ 3/а+и7а8ии )F43<22/ 2а3а8/1а7(%а +/F0(#1и4%и #1а1и#1иE/#к(> 6+аEи7(#1и и, )/3(,1+(, #),6а+9 #F и#@(0+97 1,5/%97 #(#1(,+и/7 2а8и/+1(). A(%<E/++9/ +а7и 0а++9/ #)и0/1/%&#1)<:1 (.F(1#<1#1)ии 23,7(4( +/4а1и)+(4( )%и,+и, 2а3а8/1а7(%а, и.<23(=/+а и%иF!и.<3к(%а +аF1/E/+и/ COVID-19 <F7%а0/+8/). J/6<%&1а19 и##%/0()а+и, 2(01)/350а:1 ./6(2а#+(#1& и#2(%&6()а+и, какF13а0и8и(++9@ 5а3(2(+и5а:;и@ #3/0#1), 1ак иF4(7/(2а1иE/#к(4( 23/2а3а1а !и.<3к(%®, аF1ак5/ +/(.@(0и7(#1& и+0и)и0<а%и6и3()а++(4( 2(0@(0а кF#и721(7а1иE/#к(7< %/E/+и: %и@(3а0ки <F0/1/> 2/3)(4( 4(0а 5и6+и #F3а#Iи3/+и/7 )(67(5+(#1и 23и7/+/+и, 23/2а3а1() .и(3/4<%,8и(++(> 1/3а2ии. COURSE OF COVID-19 IN CHILDREN UNDER ONE YEAR OF AGE DEPENDING ON THE TYPE OF ANTIPYRETIC THERAPY AT THE PRE-HOSPITAL STAGE D.S. Vasilkova, A.Yu. Pishchalnikov, I.N. Lupan South Ural State Medical University, Chelyabinsk For correspondence: Diniya S. Vasilkova, diva2905@mail.ru Key words: COVID-19, children under one year of age, infants, antipyretic therapy, Viburcol, paracetamol, ibuprofen, SARS-CoV-2, pre-hospital stage, fever, D-dimer, severity ofFthe disease, homeopathy, bioregulatory therapy 86 For citation: Vasilkova D.S., Pishchalnikov A.Yu. Course of COVID-19 in children under one year of age depending on the type of antipyretic therapy at the pre-hospital stage. PharmacologyF& Pharmacotherapy. 2026; 2: 86–92. DOI 10.46393/27132129_2026_2_86–92 ФАРМАК,Л,ГИЯ & ФАРМАК,&ЕРАПИЯ / /0п2ск № 2, 2026 ПЕДИА&РИЯ/PEDIATRICS Abstract A study was conducted to examine the clinical manifestations of SARS-CoV-2 infection in children under one year of age inFthe period 2021–2023. It was found that the course of the infection was predominantly mild, with no fatalities. Severe cases were associated with the presence of comorbid pathology and were accompanied by characteristic changes in laboratory markers of inUammation, as well as changes in the level..
DOI record: { "DOI": "10.46393/27132129_2026_2_86-92", "ISSN": [ "2713-2129" ], "URL": "http://dx.doi.org/10.46393/27132129_2026_2_86-92", "abstract": "<jats:p>Проведено исследование, посвященное изучению клинических проявлений инфекции SARS-CoV-2 у детей первого года жизни в период 2021–2023 гг. Установлено, что течение заболевания преимущественно было легким, без летальных исходов. Тяжелые случаи ассоциировались с наличием коморбидной патологии и сопровождались характерными изменениями лабораторных маркеров воспаления, а также уровня D-димера. При сравнительном анализе трех групп пациентов, выделенных в зависимости от вида жаропонижающей терапии на догоспитальном этапе (Вибуркол®, парацетамол, ибупрофен), статистически значимых различий по большинству клинических и лабораторных показателей не выявлено, за исключением повышенного уровня D-димера в группе ибупрофена. Тенденции к более тяжелому течению и более высокой частоте перевода в отделение реанимации в группе парацетамола не достигли статистической значимости и, вероятно, связаны с исходным тяжелым состоянием пациентов. Полученные нами данные свидетельствуют об отсутствии прямого негативного влияния парацетамола, ибупрофена или Вибуркола на течение COVID-19 у младенцев. Результаты исследования подтверждают безопасность использования как традиционных жаропонижающих средств, так и гомеопатического препарата Вибуркол®, а также необходимость индивидуализированного подхода к симптоматическому лечению лихорадки у детей первого года жизни с расширением возможности применения препаратов биорегуляционной терапии.</jats:p>\n <jats:p>A study was conducted to examine the clinical manifestations of SARS-CoV-2 infection in children under one year of age in the period 2021–2023. It was found that the course of the infection was predominantly mild, with no fatalities. Severe cases were associated with the presence of comorbid pathology and were accompanied by characteristic changes in laboratory markers of inflammation, as well as changes in the level of D-dimer. In a comparative analysis of three groups of patients with different antipyretic therapy at the pre-hospital stage (Viburkol®, paracetamol, and ibuprofen), no statistically significant differences were found in most clinical and laboratory parameters, except for an elevated D-dimer level in the ibuprofen group. The trends towards a more severe course and the frequency of transfer to the intensive care unit in the paracetamol group did not reach statistical significance and are likely related to the initial severity of the patients' condition. The findings suggest that paracetamol, ibuprofen, or Viburcol® do not have a direct negative impact on the course of COVID-19 in infants. The study results confirm the safety of using both traditional antipyretics and the homeopathic drug Viburcol®, as well as the need for an individualized approach to the symptomatic treatment of fever in infants, with an emphasis on the use of bioregulatory therapy.</jats:p>", "author": [ { "affiliation": [ { "name": "ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России" } ], "family": "Василькова", "given": "Д.С.", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "first" }, { "affiliation": [ { "name": "ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России" } ], "family": "Пищальников", "given": "А.Ю.", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "first" } ], "container-title": "Фармакология &amp; Фармакотерапия", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2026, 6, 7 ] ], "date-time": "2026-06-07T13:41:47Z", "timestamp": 1780839707000 }, "deposited": { "date-parts": [ [ 2026, 6, 7 ] ], "date-time": "2026-06-07T13:44:05Z", "timestamp": 1780839845000 }, "indexed": { "date-parts": [ [ 2026, 6, 7 ] ], "date-time": "2026-06-07T14:00:16Z", "timestamp": 1780840816558, "version": "3.54.1" }, "is-referenced-by-count": 0, "issue": "2", "issued": { "date-parts": [ [ 2026, 5, 22 ] ] }, "journal-issue": { "issue": "2", "published-print": { "date-parts": [ [ 2026, 5, 22 ] ] } }, "language": "ru", "member": "25661", "original-title": [], "page": "86-92", "prefix": "10.46393", "published": { "date-parts": [ [ 2026, 5, 22 ] ] }, "published-print": { "date-parts": [ [ 2026, 5, 22 ] ] }, "publisher": "PROFMEDPRES LLC", "reference": [ { "DOI": "10.3345/cep.2023.00794", "doi-asserted-by": "crossref", "key": "1", "unstructured": "Cimolai N. COVID-19 among infants: key clinical features and remaining controversies. Clin. Exp. Pediatr. 2024; 67 (1): 1–16." }, { "DOI": "10.1080/24694193.2021.1930288", "doi-asserted-by": "crossref", "key": "2", "unstructured": "Taheri L., Gheiasi S.F., Taher M. et al. Clinical features of COVID-19 in newborns, infants, and children: a systematic review and meta-analysis. Compr. Child. Adolesc. Nurs. 2021; 45 (2): 137–155." }, { "DOI": "10.1016/j.arcped.2020.12.008", "doi-asserted-by": "crossref", "key": "3", "unstructured": "Mansourian M., Ghandi Y., Habibi D., Mehrabi S. COVID-19 infection in children: a systematic review and meta-analysis of clinical features and laboratory findings. Arch. Pediatr. 2021; 28 (3): 242–248." }, { "DOI": "10.3389/fped.2020.591132", "doi-asserted-by": "crossref", "key": "4", "unstructured": "Li B., Zhang S., Zhang R. et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front. Pediatr. 2020; 8: 591132." }, { "DOI": "10.21037/apm-22-933", "doi-asserted-by": "crossref", "key": "5", "unstructured": "Xiao F., Tang M., Yan K., Zhou W. Clinical features of infants with SARS-CoV-2 infection: a systematic review and meta-analysis. Ann. Palliat. Med. 2022; 11 (11): 3394–3408." }, { "DOI": "10.1136/archdischild-2023-326167", "doi-asserted-by": "crossref", "key": "6", "unstructured": "Gale C., Sharkey D., Fitzpatrick K.E. et al. Neonatal complications of COVID-19 Collaborative Group. Characteristics and outcomes of neonates hospitalised with SARS-CoV-2 infection in the UK by variant: a prospective national cohort study. Arch. Dis. Child Fetal. Neonatal. Ed. 2024; 109 (3): 279–286." }, { "DOI": "10.1016/j.cmi.2020.06.003", "doi-asserted-by": "crossref", "key": "7", "unstructured": "Rinott E., Kozer E., Shapira Y. et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin. Microbiol. Infect. 2020; 26 (9): 1259.e5–1259.e7." }, { "key": "8", "unstructured": "Drake T.M., Fairfield C.J., Pius R. et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021; 3 (7): e498–e506." }, { "DOI": "10.1016/j.chest.2020.03.040", "doi-asserted-by": "crossref", "key": "9", "unstructured": "Sodhi M., Etminan M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest. 2020; 158 (1): 55–56." }, { "DOI": "10.3390/healthcare12222309", "doi-asserted-by": "crossref", "key": "10", "unstructured": "Bianconi A., Zauli E., Biagiotti C. et al. Paracetamol use and COVID-19 clinical outcomes: a meta-analysis. Healthcare (Basel). 2024; 12 (22): 2309." }, { "key": "11", "unstructured": "Mittal R., Ni R., Patel A.P. COVID-19 among infants: key clinical features and remaining controversies. Global Pediatric Health. 2023; 10: 2333794X231219426. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10764668 (accessed 18.01.2026)." }, { "DOI": "10.1056/NEJMc2005073", "doi-asserted-by": "crossref", "key": "12", "unstructured": "Lu X., Zhang L., Du H. et al. SARS-CoV-2 infection in children. N. Engl. J. Med. 2020; 382 (17): 1663–1665." }, { "DOI": "10.1136/archdischild-2020-319837", "doi-asserted-by": "crossref", "key": "13", "unstructured": "Trevisanuto D., Cavallin F., Cavicchiolo M.E. et al. Coronavirus infection in neonates: a systematic review. Arch. Dis. Child Fetal. Neonatal Ed. 2021; 106 (3): 330–335." }, { "DOI": "10.1002/jmv.26208", "doi-asserted-by": "crossref", "key": "14", "unstructured": "Ma X., Liu S., Chen L. et al. The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: a meta-analysis and systematic review. J. Med. Virol. 2021; 93 (1): 234–240." }, { "key": "15", "unstructured": "Кукес И.В., Поздняков Д.И. Фармакодинамические свойства препарата Вибуркол® с позиции иммунофармакологии. Лекарственные средства и рациональная фармакотерапия. 2025; 1 (14): 17–25." }, { "key": "16", "unstructured": "Gottwald R., Weiser M. Antihomotoxic treatment of agitation with and without fever in children; results of a post-marketing clinical study. Int. J. Biomed. Res. Ther. 1999; 28 (6): 308–312." } ], "reference-count": 16, "references-count": 16, "relation": {}, "resource": { "primary": { "URL": "https://pmp-agency.ru/ff2-2026/tpost/kpgvrozzp1-techenie-covid-19-u-detei-do-goda-v-zavi" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [ "Course of COVID-19 in children under one year of age depending on the type of antipyretic therapy at the pre-hospital stage" ], "title": "Течение COVID-19 у детей до года в зависимости от вида жаропонижающей терапии на догоспитальном этапе", "type": "journal-article" }